Antitumor activity of Chidamide in hepatocellular carcinoma cell lines

Molecular Medicine Reports

Volumn 5, Issue 6, 2012, Pages 1503-1508

  Wang, Haijuan ^a   Guo, Yi ^b   Fu, Ming ^a   Liang, Xiao ^a   Zhang, Xueyan ^a   Wang, Renzhi ^b   Lin, Chen ^a   Qian, Haili ^a  

^a CANCER HOSPITAL   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Antitumor; Apoptosis; Chidamide; p21

Indexed keywords

ANTINEOPLASTIC AGENT; CHIDAMIDE; ENTINOSTAT; MESSENGER RNA; PROTEIN P21; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; COLON CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; UPREGULATION;

AMINOPYRIDINES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; LIVER NEOPLASMS; PYRIDINES; UP-REGULATION;

EID: 84860755633     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.858     Document Type: Article

References (20)

1. Ropero S and Esteller M: The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 1: 19-25, 2007. (Pubitemid 46776612)
2. Walkinshaw DR and Yang XJ: Histone deacetylase inhibitors as novel anticancer therapeutics. Curr Oncol 15: 237-243, 2008.
3. Kelly WK and Marks PA: Drug insight: histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2: 150-157, 2005. (Pubitemid 40823166)
4. Lin HY, Chen CS, Lin SP and Weng JR: Targeting histone deacetylase in cancer therapy. Med Res Rev 26: 397-413, 2006.
5. Adler JT, Hottinger DG, Kunnimalaiyaan M and Chen H: Inhibition of growth in medullary thyroid cancer cells with histone deacetylase inhibitors and lithium chloride. J Surg Res 159: 640-644, 2010.
6. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK and Benz CC: Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45: 495-528, 2005. (Pubitemid 40261815)
7. Niesen MI and Blanck G: Rescue of major histocompatibility- DR surface expression in retinoblastoma-defective, non-small cell lung carcinoma cells by the MS-275 histone deacetylase inhibitor. Biol Pharm Bull 32: 480-482, 2009.
8. Belien A, De Schepper S, Floren W, et al: Real-time gene expression analysis in human xenografts for evaluation of histone deacetylase inhibitors. Mol Cancer Ther 5: 2317-2323, 2006. (Pubitemid 44530469)
9. Bracker TU, Sommer A, Fichtner I, Faus H, Haendler B and Hess-Stumpp H: Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models. Int J Oncol 35: 909-920, 2009.
10. Liu L, Chen B, Qin S, et al: A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells. Biochem Biophys Res Commun 392: 190-195, 2010.
11. Fournel M, Trachy-Bourget MC, Yan PT, et al: Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. Cancer Res 62: 4325-4330, 2002. (Pubitemid 34827289)
12. Catalioto RM, Maggi CA and Giuliani S: Chemically distinct HDAC inhibitors prevent adipose conversion of subcutaneous human white preadipocytes at an early stage of the differentiation program. Exp Cell Res 315: 3267-3280, 2009.
13. Roy S, Packman K, Jeffrey R and Tenniswood M: Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ 12: 482-491, 2005. (Pubitemid 40662846)
14. Gui CY, Ngo L, Xu WS, Richon VM and Marks PA: Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 101: 1241-1246, 2004. (Pubitemid 38182673)
15. Huang L, Sowa Y, Sakai T and Pardee AB: Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 19: 5712-5719, 2000.
16. Altmann A, Eisenhut M, Bauder-Wust U, Markert A, Askoxylakis V, Hess-Stumpp H and Haberkorn U: Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275. Eur J Nucl Med Mol Imaging 37: 2286-2297, 2010.
17. Takai N, Ueda T, Nishida M, Nasu K and Narahara H: Anticancer activity of MS-275, a novel histone deacetylase inhibitor, against human endometrial cancer cells. Anticancer Res 26: 939-945, 2006.
18. Okamoto H, Fujioka Y, Takahashi A, Takahashi T, Taniguchi T, Ishikawa Y and Yokoyama M: Trichostatin A, an inhibitor of histone deacetylase, inhibits smooth muscle cell proliferation via induction of p21(WAF1). J Atheroscler Thromb 13: 183-191, 2006.
19. Rosato RR, Almenara JA and Grant S: The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1. Cancer Res 63: 3637-3645, 2003. (Pubitemid 36793047)
20. Khan N, Jeffers M, Kumar S, et al: Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 409: 581-589, 2008. (Pubitemid 351184977)